Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Intercept Pharmaceuticals (Nasdaq: ICPT) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, before market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq: ICPT) will announce its fourth quarter and full year 2020 financial results on February 25, 2021, before market opening. The announcement will be followed by a conference call at 8:30 a.m. ET, where management will discuss the results. The conference call can be accessed via the investor website or through dedicated phone lines for domestic and international callers. Intercept focuses on therapeutics for progressive non-viral liver diseases such as primary biliary cholangitis and nonalcoholic steatohepatitis.
Positive
- Upcoming financial results announcement potentially signaling increased transparency for investors.
Negative
- None.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was -8.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2020 financial results prior to market open on Thursday, February 25, 2021. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.
The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 7565656. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
Source: Intercept Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.